| CAS NO: | 473921-12-9 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 200mg | 电议 |
| Cas No. | 473921-12-9 |
| 别名 | 3-氰基-5-[[3,5-二乙基-1-(2-羟基乙基)-1H-吡唑-4-基]氧基]苯腈,UK-453061;UK453061;UK 453061 |
| 化学名 | 5-[3,5-diethyl-1-(2-hydroxyethyl)pyrazol-4-yl]oxybenzene-1,3-dicarbonitrile |
| Canonical SMILES | CCC1=C(C(=NN1CCO)CC)OC2=CC(=CC(=C2)C#N)C#N |
| 分子式 | C17H18N4O2 |
| 分子量 | 310.35 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 10 mg/ml |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Lersivirine (UK-453061) is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI)for human immunodeficincy virus (HIV) infection with IC50 value of 119 nM [1]. HIV is a retro virus that causes HIV infection and acquired immunodeficiency syndrome (AIDS). It may infect vital cells of human immune system such as helper T cells and dendritic cells. HIV transcriptase plays an important role in the infection process. HIV carries a reverse transcriptase which can transcript single-stranded virus RNA into double-stranded DNA. When the virus anchor to the target cell surface, the reverse transcriptase will be injected into host cell, there it may complete the transcription. And the transcribed DNA is able to integrate into host genome to complete infection and viral replication. Lersivirine (UK-453061) is a NNRTI with a unique resistance profile that exhibits potent antiretroviral activity against wild-type HIV and clinically relevant NNRTI-resistant strains. When lersivirine was tested with a panel of isolated wild-type and drug-resistant HIV reverse transcriptase, it exhibited excellent inhibitory activity, which confirmed the high potency of it as the next-generation anti-HIV NNRTI. The compound also has good aqueous solubility and formulation characteristics which enable further in vivo evaluation [2]. Mated Crl:CD1 mice were administered 0, 150, 350, and 500 mg/kg lersivirine once daily by oral gavage on gestation days 6 to 17, followed by cesarean section on gestation day 18. The first 2 days of dosing for the high-dose group were done at 250 mg/kg to allow induction of hepatic metabolizing enzymes, after which the dose was increased to 500 mg/kg/day. Exposure of lersivirine did not cause any increases in external, visceral, or skeletal malformation, which demonstrated lersivirine is not teratogenic in mice [3]. References: |
m.cnreagent.com